Table II.
Summary of clinical studies of the G719X mutation in EGFR.
| Research type | Article | Mutation | TKI | Total cases | Response | RR/% | Sensitivity | Ref. | |
|---|---|---|---|---|---|---|---|---|---|
| Retrospective studies | |||||||||
| Summary of cases | This article | G719X | E/G | 134 | 47 | 35.1% | Intermediate | Table I | |
| Reviews | Mistudomi 2006 and 2007 | G719X | E/G | 9 | 5 | 55.6 | Intermediate | 44,45 | |
| Kobayashi 2015 | G719X | G | 3 | 2 | 66.7 | Intermediate | 16 | ||
| Klughammer 2016 | G719X | E | 2 | 1 | 50 | Intermediate | 46 | ||
| Meta-analysis | Not found | ||||||||
| Prospective studies | |||||||||
| Observational | Arrieta 2015 | G719X | E/G/A | 11 | NAa | NA | Not known | 47 | |
| Clinical trials | Not found |
a
The response rate of the G719X mutation were not discussed separately. G, gefitinib; E, erlotinib; A, Afatinib; RR, response rate; NA, not accessible. Sensitivity cut-off values: ≥0 RR <25%, resistant; ≥25% RR <75%, intermediately sensitive; ≥75% RR ≤100%, sensitive.